Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Fineline Cube Apr 20, 2026
Company Drug

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

Fineline Cube Apr 20, 2026
Company Deals

Innovent Biologics Partners with Suzhou ForLong to Explore Sintilimab and FL115 Combination in Solid Tumors

Fineline Cube Dec 26, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has announced a clinical study and supply agreement with...

Company Deals

Zhejiang Huahai Pharmaceutical’s Subsidiary Huaota Bio Secures $27.4 Million Investment

Fineline Cube Dec 26, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that its macromolecular drug-focused subsidiary, Shanghai...

Company Drug

Bristol-Myers Squibb’s Sotyktu Meets Primary Endpoints in POETYK PsA Studies

Fineline Cube Dec 25, 2024

US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from the pivotal...

Company Deals

Bio-Thera Solutions Enters Licensing Agreement with Tabuk Pharmaceutical for BAT2206 in Saudi Arabia

Fineline Cube Dec 25, 2024

China-based Bio-Thera Solutions (SHA: 688177) has announced a licensing agreement with Tabuk Pharmaceutical Manufacturing Company,...

Company Deals

Achilles Therapeutics and AstraZeneca Seal $12 Billion Deal for TRACERx NSCLC Study Data

Fineline Cube Dec 25, 2024

UK-based Achilles Therapeutics plc has announced a landmark deal worth USD 12 billion with AstraZeneca...

Company Drug

Nuvation Bio’s Taletrectinib NDA for ROS1+ NSCLC Receives FDA Priority Review

Fineline Cube Dec 25, 2024

US-based Nuvation Bio Inc. (NYSE: NUVB) has announced that the New Drug Application (NDA) for...

Company Drug

Shanghai Henlius Biotech Initiates Patient Dosing in Global Phase III ELAINE-3 Study for Lasofoxifene

Fineline Cube Dec 25, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Medical Device

RaysightMed’s AngioQFA 100 Receives NMPA Approval for Coronary Artery Function Measurement

Fineline Cube Dec 25, 2024

China-based RaysightMed Co., Ltd has announced that it has received marketing approval from the National...

Company Deals

uBriGene Secures RMB 200 Million in Pre-Series D Financing to Expand ATMPs CDMO Services

Fineline Cube Dec 25, 2024

China-based uBriGene, a contract development and manufacturing organization (CDMO) focused on advanced therapy medicinal products...

Company Deals

WuXi AppTec to Divest WuXi Advanced Therapies and Oxford Genetics to Altaris LLC

Fineline Cube Dec 25, 2024

China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec Co., Ltd (SHA: 603259) has announced...

Company Deals

Basecare Medical and SolarCare Form Alliance to Advance AI in IVF Services

Fineline Cube Dec 25, 2024

Suzhou Basecare Medical Co., Ltd (HKG: 2170), a leading China-based in vitro fertilization (IVF) specialist,...

Company Drug

Alphamab Oncology’s JSKN033 Gets Green Light for Phase I/II Study from China’s CDE

Fineline Cube Dec 25, 2024

China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...

Company Drug

CSPC Pharmaceutical’s SYH2062 Receives NMPA Clearance for Hypertension Treatment

Fineline Cube Dec 24, 2024

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...

Company Drug

Keymed Biosciences’ Kangyueda Approved for CRSwNP Treatment in China

Fineline Cube Dec 24, 2024

China-based Keymed Biosciences Inc., (HKG: 2162) has announced that it has received another indication approval...

Company Drug

Sichuan Biokin’s GNC-038 Tetra-Specific Antibody Clears for Clinical Trials in Autoimmune Diseases

Fineline Cube Dec 24, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Drug

Changchun High & New Technology Industries Receives FDA Approval for Menopausal VMS Drug Trial

Fineline Cube Dec 24, 2024

China-based Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has received the green...

Company Drug

AstraZeneca’s Tagrisso Secures EU Approval for EGFR-Mutated Locally Advanced NSCLC

Fineline Cube Dec 24, 2024

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that the European Commission (EU) has...

Company Deals

Ikena Oncology and Inmagene Biopharmaceuticals to Merge into ImageneBio, Listed on Nasdaq as ‘IMA’

Fineline Cube Dec 24, 2024

US-based Ikena Oncology, Inc. (NASDAQ: IKNA) and Sino-US biotech Inmagene Biopharmaceuticals have announced their merger...

Company Deals

Sanofi and SK bioscience Broaden Partnership to Develop Next-Gen Pneumococcal Vaccines

Fineline Cube Dec 24, 2024

French pharmaceutical major Sanofi (NASDAQ: SNY) and South Korea-based SK bioscience (KRX: 302440) have announced...

Company Deals

Corxel Pharmaceuticals Secures Global Rights to CX11, a Novel Oral GLP-1 RA, in Licensing Deal with Vincentage

Fineline Cube Dec 24, 2024

China-based Corxel Pharmaceuticals (CORXEL) has announced a significant licensing agreement with domestic firm Vincentage, securing...

Posts pagination

1 … 227 228 229 … 654

Recent updates

  • Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication
  • UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection
  • Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors
  • Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium
  • Eli Lilly Launches Omvoh (Mirikizumab) in China for Inflammatory Bowel Disease – IL-23p19 Antagonist Targets Ulcerative Colitis and Crohn’s Disease Following February Approval
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Company Drug

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.